Report cover image

Small Molecule Multi-target Angiogenesis Inhibitor Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 07, 2025
Length 129 Pages
SKU # APRC20260572

Description

Summary

According to APO Research, the global Small Molecule Multi-target Angiogenesis Inhibitor market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Small Molecule Multi-target Angiogenesis Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Small Molecule Multi-target Angiogenesis Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Small Molecule Multi-target Angiogenesis Inhibitor is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor include Chia Tai Tianqing, Teva, Jiangsu Hengrui Pharmaceuticals, TWi Pharmaceuticals, Sanofi, Pfizer, Novartis, Janssen Biotech and Exelixis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Small Molecule Multi-target Angiogenesis Inhibitor, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Small Molecule Multi-target Angiogenesis Inhibitor.

The report will help the Small Molecule Multi-target Angiogenesis Inhibitor manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Small Molecule Multi-target Angiogenesis Inhibitor market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Small Molecule Multi-target Angiogenesis Inhibitor market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Company

Chia Tai Tianqing
Teva
Jiangsu Hengrui Pharmaceuticals
TWi Pharmaceuticals
Sanofi
Pfizer
Novartis
Janssen Biotech
Exelixis
Eisai
Boehringer Ingelheim
Bayer
AstraZeneca.
Small Molecule Multi-target Angiogenesis Inhibitor Segment by Type

Apatinib
Axitinib
Anlotinib
Vandetanib
Cabozantinib
Lenvatinib
Pazopanib
Sunitinib
Sorafenib
Other
Small Molecule Multi-target Angiogenesis Inhibitor Segment by Application

Cancer Therapy
Inflammatory and Autoimmune Diseases
Ophthalmic Diseases
Other
Small Molecule Multi-target Angiogenesis Inhibitor Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Small Molecule Multi-target Angiogenesis Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Small Molecule Multi-target Angiogenesis Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Small Molecule Multi-target Angiogenesis Inhibitor.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Small Molecule Multi-target Angiogenesis Inhibitor manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Small Molecule Multi-target Angiogenesis Inhibitor by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Small Molecule Multi-target Angiogenesis Inhibitor in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

129 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size (2020-2031)
2.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (2020-2031)
2.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Average Price (2020-2031)
2.3 Small Molecule Multi-target Angiogenesis Inhibitor by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Apatinib
2.3.3 Axitinib
2.3.4 Anlotinib
2.3.5 Vandetanib
2.3.6 Cabozantinib
2.3.7 Lenvatinib
2.3.8 Pazopanib
2.3.9 Sunitinib
2.3.10 Sorafenib
2.3.11 Other
2.4 Small Molecule Multi-target Angiogenesis Inhibitor by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Cancer Therapy
2.4.3 Inflammatory and Autoimmune Diseases
2.4.4 Ophthalmic Diseases
2.4.5 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue of Manufacturers (2020-2025)
3.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Average Price by Manufacturers (2020-2025)
3.5 Global Small Molecule Multi-target Angiogenesis Inhibitor Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Product Type & Application
3.8 Global Manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor, Established Date
3.9 Global Small Molecule Multi-target Angiogenesis Inhibitor Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Chia Tai Tianqing
4.1.1 Chia Tai Tianqing Company Information
4.1.2 Chia Tai Tianqing Business Overview
4.1.3 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.1.5 Chia Tai Tianqing Recent Developments
4.2 Teva
4.2.1 Teva Company Information
4.2.2 Teva Business Overview
4.2.3 Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.2.5 Teva Recent Developments
4.3 Jiangsu Hengrui Pharmaceuticals
4.3.1 Jiangsu Hengrui Pharmaceuticals Company Information
4.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
4.3.3 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
4.4 TWi Pharmaceuticals
4.4.1 TWi Pharmaceuticals Company Information
4.4.2 TWi Pharmaceuticals Business Overview
4.4.3 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.4.4 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.4.5 TWi Pharmaceuticals Recent Developments
4.5 Sanofi
4.5.1 Sanofi Company Information
4.5.2 Sanofi Business Overview
4.5.3 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.5.5 Sanofi Recent Developments
4.6 Pfizer
4.6.1 Pfizer Company Information
4.6.2 Pfizer Business Overview
4.6.3 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.6.4 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.6.5 Pfizer Recent Developments
4.7 Novartis
4.7.1 Novartis Company Information
4.7.2 Novartis Business Overview
4.7.3 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.7.4 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.7.5 Novartis Recent Developments
4.8 Janssen Biotech
4.8.1 Janssen Biotech Company Information
4.8.2 Janssen Biotech Business Overview
4.8.3 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.8.5 Janssen Biotech Recent Developments
4.9 Exelixis
4.9.1 Exelixis Company Information
4.9.2 Exelixis Business Overview
4.9.3 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.9.5 Exelixis Recent Developments
4.10 Eisai
4.10.1 Eisai Company Information
4.10.2 Eisai Business Overview
4.10.3 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.10.5 Eisai Recent Developments
4.11 Boehringer Ingelheim
4.11.1 Boehringer Ingelheim Company Information
4.11.2 Boehringer Ingelheim Business Overview
4.11.3 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.11.5 Boehringer Ingelheim Recent Developments
4.12 Bayer
4.12.1 Bayer Company Information
4.12.2 Bayer Business Overview
4.12.3 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.12.5 Bayer Recent Developments
4.13 AstraZeneca.
4.13.1 AstraZeneca. Company Information
4.13.2 AstraZeneca. Business Overview
4.13.3 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2020-2025)
4.13.4 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
4.13.5 AstraZeneca. Recent Developments
5 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Scenario by Region
5.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2020-2031
5.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2020-2025
5.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region: 2026-2031
5.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2020-2031
5.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2020-2025
5.3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Region: 2026-2031
5.4 North America Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
5.4.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2020-2031)
5.4.3 North America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
5.5.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2020-2031)
5.5.3 Europe Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
5.6.1 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2020-2031)
5.6.3 Asia Pacific Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
5.7.1 South America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2020-2031)
5.7.3 South America Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.7.7 Colombia
5.8 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Facts & Figures by Country
5.8.1 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2020-2031)
5.8.3 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2020-2031)
6.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2020-2031) & (K Units)
6.1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Type (2020-2031)
6.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Type (2020-2031)
6.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Type (2020-2031)
6.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Price by Type (2020-2031)
7 Segment by Application
7.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2020-2031)
7.1.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2020-2031) & (K Units)
7.1.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Application (2020-2031)
7.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue by Application (2020-2031)
7.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Application (2020-2031)
7.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Small Molecule Multi-target Angiogenesis Inhibitor Value Chain Analysis
8.1.1 Small Molecule Multi-target Angiogenesis Inhibitor Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Small Molecule Multi-target Angiogenesis Inhibitor Production Mode & Process
8.2 Small Molecule Multi-target Angiogenesis Inhibitor Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Small Molecule Multi-target Angiogenesis Inhibitor Distributors
8.2.3 Small Molecule Multi-target Angiogenesis Inhibitor Customers
9 Global Small Molecule Multi-target Angiogenesis Inhibitor Analyzing Market Dynamics
9.1 Small Molecule Multi-target Angiogenesis Inhibitor Industry Trends
9.2 Small Molecule Multi-target Angiogenesis Inhibitor Industry Drivers
9.3 Small Molecule Multi-target Angiogenesis Inhibitor Industry Opportunities and Challenges
9.4 Small Molecule Multi-target Angiogenesis Inhibitor Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.